Sreejesh Sreedharanunni

51 posts

Sreejesh Sreedharanunni

Sreejesh Sreedharanunni

@drssreejesh

Hematopathologist, Additional professor, @PGIMER.

Chandigarh, India Katılım Aralık 2023
172 Takip Edilen149 Takipçiler
Sreejesh Sreedharanunni retweetledi
Rahul Banerjee, MD, FACP
Rahul Banerjee, MD, FACP@RahulBanerjeeMD·
Excellently written #CLML article about myeloma treatment in South Asia. 70% of #MMsm expenditures in 🇮🇳 🇵🇰 🇱🇰 🇧🇩 et al paid out of pocket by pts. Over half of public institutions don't have access to FLC testing, let alone SPEP... We have work to do! sciencedirect.com/science/articl…
Rahul Banerjee, MD, FACP tweet media
English
2
10
26
5K
Sreejesh Sreedharanunni retweetledi
HematPGI
HematPGI@HematPgi·
Much awaited Hemat focused NGS Workshop at PGI, Chandigarh on Sept 25–26, 2025— covering library prep, reporting guidelines, platform demos, and bioinformatics pipelines! Register now; seats limited to the first 50 participants. Scan & pay #NGS @drssreejesh @DrPMPGI
HematPGI tweet mediaHematPGI tweet media
English
0
7
19
1K
Sreejesh Sreedharanunni retweetledi
Vikram Deshpande
Vikram Deshpande@Vik_deshpandeMD·
This is directed at the authors, editors, and administrators of the WHO Blue Books: 1️⃣ If a chapter relies on genetic testing unavailable to >80% of the world, it serves no one but those who already know the disease. Rewrite it. 2️⃣ If you plan to change nomenclature, ask: Does it change practice? Does it impact clinical care? If not—don’t change it. 3️⃣ If you’re adding IHC to diagnostic criteria and it’s unavailable in most countries, don’t include it—unless you’re willing to pay for it. 4️⃣ Don’t create a new entity based solely on molecular testing if it’s not actionable and/or not visible on H&E. 5️⃣ For every chapter you write, ask yourself: “Am I reducing global health inequity or increasing it?” If the answer isn’t crystal clear, start over.
English
31
69
245
16.1K
Sreejesh Sreedharanunni retweetledi
Gaurav Prakash M.D.
Gaurav Prakash M.D.@DrGPrakash·
The vision and the visionary. Prof @DrPMPGI has excellently conceived and lead a unique initiative in India to advance field of multiple myeloma research and care. Kudos! @IndMyAcGp #Image2025
Gaurav Prakash M.D. tweet mediaGaurav Prakash M.D. tweet media
English
0
8
37
4.8K
Sreejesh Sreedharanunni retweetledi
Uday Yanamandra
Uday Yanamandra@UdayYanamandra·
Come January 2025 and, we await the next edition of the Indian Myeloma Congress by IMAGe (@IndMyAcGp). We have an exciting lineup of lectures and interactions with Who's Who of Myeloma. Know your faculty. #TMCKolkata #IndianMyelomaCongress2025
Uday Yanamandra tweet mediaUday Yanamandra tweet mediaUday Yanamandra tweet mediaUday Yanamandra tweet media
English
2
9
22
5K
Sreejesh Sreedharanunni retweetledi
HematPGI
HematPGI@HematPgi·
🚨 Join us for an exclusive webinar with Dr. Guilin Tang from MD Anderson Cancer Center on Optical Genome Mapping (OGM) in Hematological Disorders! 🚨 🗓️ Date: Aug 28, 2024
🕣 Time: 7:00 PM (IST) | 8:30 AM (Houston)
💻 Venue: Online Register via QR code. Hosted by Hemat PGI CHD
HematPGI tweet mediaHematPGI tweet media
English
1
5
6
414
Sreejesh Sreedharanunni retweetledi
THE CYTOMETRY SOCIETY
THE CYTOMETRY SOCIETY@CytometryIndia·
CLPDs are often easy to diagnose by #flowcytometry, but every now & then comes a case that throws us off course. How do we approach these systematically? What markers are essential in our panels? Find out these & more from the experts at the #CLPD workshop at #FlowTCS2024!
THE CYTOMETRY SOCIETY tweet media
English
0
2
7
413